Magali Haas

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. pmc An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia
    Gahan Pandina
    Janssen Research and Development, LLC, 1125 Trenton Harbourton Road, Titusville, NJ, 08560, USA
    Child Adolesc Psychiatry Ment Health 6:23. 2012
  2. doi request reprint Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study
    Magali Haas
    Johnson and Johnson Pharmaceutical Research and Development, Division of Janssen Pharmaceutica NV, Beerse, Belgium
    Br J Psychiatry 194:158-64. 2009
  3. doi request reprint Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study
    Magali Haas
    Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium
    Bipolar Disord 11:687-700. 2009
  4. doi request reprint A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia
    Magali Haas
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, New Jersey, USA
    J Child Adolesc Psychopharmacol 19:611-21. 2009
  5. doi request reprint Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents
    Magali Haas
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, New Jersey 08530, USA
    J Child Adolesc Psychopharmacol 18:337-45. 2008

Detail Information

Publications5

  1. pmc An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia
    Gahan Pandina
    Janssen Research and Development, LLC, 1125 Trenton Harbourton Road, Titusville, NJ, 08560, USA
    Child Adolesc Psychiatry Ment Health 6:23. 2012
    ..abstract:..
  2. doi request reprint Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study
    Magali Haas
    Johnson and Johnson Pharmaceutical Research and Development, Division of Janssen Pharmaceutica NV, Beerse, Belgium
    Br J Psychiatry 194:158-64. 2009
    ..Effective treatments for adolescent schizophrenia are needed...
  3. doi request reprint Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study
    Magali Haas
    Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium
    Bipolar Disord 11:687-700. 2009
    ..To evaluate the efficacy, safety, and tolerability of risperidone monotherapy for the treatment of an acute mixed or manic episode in children and adolescents with bipolar I disorder...
  4. doi request reprint A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia
    Magali Haas
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, New Jersey, USA
    J Child Adolesc Psychopharmacol 19:611-21. 2009
    ..The aim of this study was to evaluate the efficacy and safety of two dose ranges of risperidone in adolescents with schizophrenia...
  5. doi request reprint Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents
    Magali Haas
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, New Jersey 08530, USA
    J Child Adolesc Psychopharmacol 18:337-45. 2008
    ..The aim of this study was to determine the long-term safety of risperidone as maintenance therapy in children and adolescents with disruptive behavior disorders (DBDs) and normal intelligence...